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Patients with end-stage renal failure owing to primary
hyperoxaluria type 1 (PH1) receive dialysis while waiting for
transplantation. So far, dialysis has not been shown to
overcome the problem of ongoing oxalate production and
deposition at extrarenal sites. We report on six children with
PH1 who had to be dialyzed for a median period of 2.5 years
while awaiting liver transplantation. Aiming at preventing
oxalate tissue accretion, oxalate mass transfer was studied
and dialysis intensified accordingly. Mean plasma oxalate
concentration was between 51 and 137 lmol/l. In three of the
six patients with a urinary output between 630 and 3140 ml,
urinary removal of oxalate was between 5.6 and 12.4 mmol/
week/1.73 m2. Hemodialysis (HD) in five of the six patients
demonstrated a mean oxalate dialysance between 158 and
444 l/week/1.73 m2. Peritoneal dialysis (PD) in two of the six
patients showed mean oxalate clearances of 66 and 103 l/
week/1.73 m2. One patient received HD and PD. By adding all
modes of elimination, a mean total oxalate mass between
10.1 and 24.1 mmol/week/1.73 m2 was removed. Dialysis is
still necessary as a temporary therapy for a number of
patients with PH1. Dialysis should be instituted pre-emptively
and maximally exploited by intensified HD/PD treatment
protocols, without, however, cutting back urinary output.
Kidney International (2006) 70, 1642–1648. doi:10.1038/sj.ki.5001806;
published online 6 September 2006
KEYWORDS: primary hyperoxaluria type 1; dialysis; oxalate; clearance;
dialysance; removal
Primary hyperoxaluria type 1 (PH1) is an autosomal-
recessive disorder caused by a deficiency of the liver-specific
peroxisomal enzyme alanine-glyoxylate-aminotransferase
(AGT). It is characterized by marked heterogeneity at the
enzymatic level. A number of different point mutations in the
gene of AGT have been identified in patients with PH1.
Neither the AGT genotype nor the degree of enzyme
deficiency has been shown to predict clinical phenotype.
The deficiency of AGT in the peroxisomes leads to
excessive generation of oxalate from glyoxalate metabolism.
The only relevant route of excretion of the metabolic end
product of oxalate is by renal filtration and secretion. The
precipitation of the highly insoluble calcium salt leads to
nephrocalcinosis and urolithiasis. Consequently, renal func-
tion decreases progessively. With advancing renal failure
plasma oxalate rises. Above a plasma oxalate concentration of
50 mmol/l, the solubility of calcium oxalate in plasma is
exceeded,1 and extrarenal deposition of oxalate at tissues like
bone, retina, myocardium, and arteries begins. This state of
the disease is called oxalosis. The relationship between the
level of renal function and the degree of supersaturation
varies considerably between patients.2
Unless the patient responds to pyridoxine, the definitive
treatment is a liver graft that serves as both enzyme
replacement and gene therapy. For patients with advanced
or end-stage renal failure (ESRF), a combined liver and
kidney transplantation (LKT) is the treatment of choice.3–5 It
can be performed as a simultaneous or a two-stage
procedure. However, patients often have to wait for
transplantation. The major dilemma of renal replacement
therapy (RRT) is that all forms of dialysis are inadequate to
keep up with the high production rate of oxalate. This results
in continuing tissue deposition of oxalate and the mentioned
risks of further organ damage. Marangella et al.6 assessed
oxalate production rate at 28.9 and 37.7 mmol/week in two
adult patients by deriving it from the linear increase of
plasma oxalate in the early phase after hemodialysis (HD).
Previous studies suggest that removal of oxalate by HD
exceeds that by peritoneal dialysis (PD).7–9
There is very little information about management of
pediatric patients with PH1 and advanced or ESRF who have
to wait for definitive treatment. To remedy this situation, we
studied plasma oxalate concentration, oxalate clearance, and
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oxalate removal of our six patients who received RRT while
awaiting transplantation. Treatment protocols were adjusted
according to our results. In an attempt to reduce tissue
accretion rate of oxalate, the obvious aim was to reduce
plasma oxalate concentration below the level at the start of
intensified treatment, and ideally below the threshold for
supersaturation of 50 mmol/l.
RESULTS
The median time between the start of dialysis and liver
transplantation was 2.5 years (range 0.8–5.5 years). During
the course of study, plasma oxalate concentration was
determined 5–10 times per patient. As can be seen in Table 1,
the plasma oxalate concentration at the start of dialysis could
be reduced in all but one patient (D) during the period of
intensified dialysis. The parents of patient D did not agree to
a further investment of time in RRT. However, plasma oxalate
of patients E and F rose again following episodes of partial
occlusion of vascular access (patient E), and catheter-related
septicemia and peritonitis (patient F), respectively.
Searching for a more effective mode of oxalate elimination
via HD, different dialyzers and blood flow rates (QB) were
evaluated. The use of a dialyzer with a larger surface and a
high flux membrane as compared to a smaller surface and a
low flux membrane resulted in a higher reduction of plasma
oxalate (patient D; Figure 1). Similarly, the positive influence
of a higher QB on the removal of oxalate by HD could be
demonstrated (patient F; Figure 2). The comparison of pre-
dialysis to post-dialysis values showed that reduction of
plasma oxalate concentration in all patients undergoing HD
exceeded 80% when the most intensive regimen was applied
(data only shown for patients D and F; Figures 1 and 2). The
graphs also give an account of the rebound of oxalate to the
plasma pool after terminating an HD session.
Peritoneal equilibration tests over 4 h were carried out for
patients A and F showing full equilibration for oxalate.
Dialysate/plasma ratios of oxalate in patient A were 0.41,
0.66, and 0.95 after 1, 2, and 3 h. Assuming an exponential
function with a negative coefficient for the concentration
versus time relationship, and outweighing the loss of time
while dialysate has to be exchanged, we chose a dwell time of
60 min per cycle. Consequently, patients A and F underwent
continuous cyclic peritoneal dialysis with 10 cycles at night
and one or two additional exchanges during the day. Table 2
presents our intensified treatment protocols and the total
creatinine clearance, which gives an impression of the dialysis
intensity achieved. Clearance, dialysance, and removal of
oxalate are given in Table 3.
For illustration, a management report of patient F is given
in detail (Figure 3). At presentation at an age of 5 months,
the patient’s plasma oxalate was 179 mmol/l, and her
creatinine clearance was 25 ml/min/1.73 m2. She was treated
by urinary dilution and urinary crystallization inhibition.
Thereby her plasma oxalate concentration could only be
reduced to 120 mmol/l. Hence, she was started on continuous
ambulatory peritoneal dialysis, although her creatinine
clearance still was 15 ml/min/1.73 m2 at that time. By
increasing the dwell volume and the number of daily
exchanges, dialysance and removal of oxalate by PD
increased, even more so when continuous cyclic peritoneal
Table 1 | Plasma oxalate concentrations during the PIRD
Patient
PIRD
(months4)
OxalatePlasma
at the starta
of PIRD
(lmol/l)
Minimal
oxalatePlasma
during PIRD
(lmol/l)
OxalatePlasma
at the endb
of PIRD
(lmol/l)
A 6 109 41 50
B 2 134 105 109
C 13 86 67 67
D 6 92 92 140
E 9 144 100 107
F 8 120 62 139
PIRD, period of intensive regimen of dialysis.
All concentrations of oxalatePlasma were determined pre-dialysis.
aIn patients who were referred to our hospital: if available last measurement before
treatment in our center or at the start of dialysis in our center.
bImmediately before liver transplantation.
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Figure 1 | Influence of dialyzer (patient D). Blood flow rate was
150 ml/min for each measurement. Plasma oxalate is given in
proportion to initial plasma oxalate at each session of HD. Surface
area and type of membrane of the different hemodialyzers are
specified in the legend.
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Figure 2 | Influence of blood flow rate (patient F). Each
measurement was carried out with the hemodialyzer F30 by
Fresenius (0.4 m2, high flux). Plasma oxalate is given in proportion
to initial plasma oxalate at each session of HD.
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dialysis was instituted. Nevertheless, plasma oxalate was still
high (between 100 and 120 mmol/l) and severe osteopathy
documented by X-ray developed. In addition, three sessions
of HD per week were started. On those days, the additional
exchange of dialysate during the day had to be omitted,
which might be the reason for the slightly reduced PD
clearance. It was noted that urinary clearance on the day of
HD was lower than compared with the subsequent day
(marked by *). Instabilities of blood pressure may have
accounted for that. As total clearance and removal rate had
not improved sufficiently, the surface of the hemodialyzer,
the blood flow, and the duration of a single HD session were
increased step by step. Hence, dialysance and removal of
oxalate rose. First, plasma oxalate dropped to 62 mmol/l, but
went up drastically when a catheter-related septicemia and a
peritonitis occurred. Probably, the tissue oxalate already
deposited in the bone was another factor for plasma oxalate
not to come down.
Clinical outcome after transplantation was as follows:
patients A and E had a combined liver and kidney
transplantation, all other patients underwent a two-stage
transplant procedure. Patients B, C, D, and F received in situ
split liver transplantation (living donor in patient B). With
the exception of patient D, all hepatic grafts function
appropriately. Patient D suffered from chronic cholangitis
of the graft and died from right cardiac failure immediately
after a second hepatic graft had been implanted. Plasma
oxalate concentrations of patients A, E, and F were below
20 mmol/l within 1 month after transplantation of the kidney.
Patients B and C had a plasma oxalate concentration of 41
and 31 mmol/l, respectively, at 1 month post-kidney trans-
plantation and received concomitant HD. Patient B lost his
first renal transplant by a septicemia and still awaits his
second kidney transplant. The other children had adequately
functioning renal grafts at last follow-up. Patients B and C
still suffer from oxalosis osteopathy with skeletal deformities
Table 2 | Data on dialysis
Patient
Time on dialysis/PIRD
(years) Mode of dialysis during PIRD
Total CCr during PIRD (mean)
(l/week/1.73 m2)
A 2.6/0.5 CCPD (10+1) 40 ml/kg/day 143
B 5.5/0.2 HD 6 4.5 h/week (150 ml/min, 1.6 m2, high flux) 214
C 4.3/1.1 HD 4 4 h/week (150 ml/min, 0.7 m2, high flux) 206
D 1.1/0.5 HD 4 4 h/week (150 ml/min, 0.7 m2, high flux) 177
E 0.8/0.8 HD 5 4 h/week (170 ml/min, 0.7 m2, high flux) 172
F 0.9/0.7 CCPD
+HD
(10+1) 40 ml/kg/day
3 3.5 h/week (150 ml/min, 0.7 m2, high flux)
185
HD, hemodialysis; CCPD, continuous cyclic peritoneal dialysis; PIRD, period of intensive regimen of dialysis; CCr, creatinine clearance.
In case of CCPD, the number of exchanges per day and the dwell volume are given.
For HD, blood flow rate and characteristics of the hemodialyzer (surface area and type of membrane) are given.
Table 3 | Oxalate kinetics
Patient
BSA (mean)
(m2)
OxalatePlasma (mean)
(lmol/l)
Diuresis
(mean)
(ml/day)
Mode of
elimination
ClearanceOxalate/
DialysanceOxalate (mean)
(l/week/1.73 m2)
RemovalOxalate (mean)
(mmol/week/1.73 m2)
A 0.56 51 1900 Urine 138 5.6
CCPD 103
S 241
4:5
S 10:1
B 0.80 117 0 HD 444 24.1
C 0.47 82 0 HD 158 12.4
D 0.54 132 0 HD 342 20.2
E 1.47 137 3140 Urine 95 12.4
HD 164
S 259
10:6
S 23:0
F 0.47 111 630 Urine 88 6.6
CCPD 66 5.7
HD 222
S 376
7:3
S 19:6
BSA, body surface area; HD, hemodialysis; CCPD, continuous cyclic peritoneal dialysis.
All concentrations of oxalatePlasma were determined pre-dialysis.
For the calculation of mean clearance and mean removal rate of oxalate, only measurements of the patient’s final regime (as given in Table 2) were included; however,
irrespective of actual blood flow. Clearance, dialysance, and removal of oxalate were determined three to five times per patient. Means of these measurements as well as
mean total clearance and mean total removal rate are listed in columns 6 and 7. Corresponding concentrations of plasma oxalate and body surface areas for these
calculations are given in columns 2 and 3.
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acquired before referral to our hospital. Both are wheel chair
ridden. Beyond that, no other apparent clinical signs of
extrarenal morbidity from PH1 are apparent in any patient.
DISCUSSION
Various strategies for liver and liver–kidney transplantation
for PH1 have emerged. Although there are promising reports
of a pre-emptive liver transplantation,10,11 this treatment
option remains controversial,5,12 for reasons of unpredict-
ability of the course of disease, difficult timing, and dis-
appointing survival rates. Therefore, combined liver–kidney
transplantation is still the mode of treatment carried out in
most cases.3,5 In the meantime, RRT remains necessary to
treat renal failure and to eliminate oxalate. So far, neither HD
nor PD has been shown to achieve a rate of oxalate removal
that matches the tissue oxalate accretion rate. In order to
prevent the patient from progressing to a poor clinical state
before transplantation, an optimal RRT program must be
instituted.
There is no good relationship between the enzyme
deficiency and clinical severity of PH1. This can also be seen
among this group of patients whose history of presentation,
age at ESRF, and plasma oxalate at ESRF varied widely.
Hence, RRT of patients with PH1 has to meet individual
requirements.
Urinary excretion of oxalate, as in patients A, E, and F,
accounted for a relevant amount of total oxalate removal (55,
54, and 34% in patients A, E, and F, respectively). This fact
supports the notion that all measures should be taken to
maintain urinary excretion, including the minimization of
dehydration and hypotension.
During HD, the elimination rate of plasma oxalate is
efficient enough to overcome the production rate of
endogenous oxalate. Owing to the poor solubility and the
very slow mobilization of calcium oxalate from tissue deposits,
the blood pool is not refilled fast enough to keep up with the
elimination rate. However, as soon as the HD treatment is
stopped, a considerable rebound is present. This has also been
described by Hoppe et al.9 for pediatric and Marangella et al.6
for adult patients with secondary and primary hyperoxaluria.
As a result of the decreasing plasma oxalate, HD itself loses
effectiveness during each session, even though dialysance is
supposed to remain stable. We consider this to be the main
factor that accounts for the discrepancy between rather high
dialysances and comparably low corresponding total removal
rates of oxalate in HD. From this, we conclude that additional
sessions per week rather than a prolongation of a single session
will improve removal of oxalate. Plasma oxalate concentration
of patients B and E only came down when five and six sessions
per week were prescribed. This way of intensifying dialysis
does not seem to be acceptable for all patients as our
experience with patient D shows.
In contrast to HD, PD does not show high elimination
rates per time. Each extra PD cycle per day substantially adds
to the total removal of oxalate. However, the prescription of
dialysis should be within a reasonable range for patients and
their families.
Combination of HD and PD as proposed by Bunchman
and Swartz13 proved to increase overall removal of oxalate in
patient F. However, addition of a standard HD regimen did
not remove significantly more oxalate as compared to the
intensive PD regimen. Only by using a considerably higher QB
and a dialyzer with a higher surface than normal, an increase
of dialysance and removal of oxalate as well as a drop of
plasma oxalate concentration were achieved. However, com-
bining both methods of dialysis implies the risk of being struck
with complications of both HD and PD as seen in our patient.
Furthermore, HD might restrict the part of oxalate eliminated
via urine and PD during the session and in the early
interdialytic phase. By sequential measurements of plasma
oxalate during the interdialytic time in two patients with PH1,
Marangella et al.6 found that there was an early phase of linear
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Figure 3 | Plasma oxalate, clearance of oxalate, and removal of
oxalate in patient F. White columns represent urine, gray columns
PD, and black columns HD. The period of collecting urine and
dialysate started 8’o clock and ended the following morning. The
HD session was interposed. There was one exception: the marked
measurement (*) was carried out on a day immediately following a
day with HD. The results of oxalate clearance and oxalate removal of
HD of a single session were multiplied with the number of sessions
per week and divided by seven. Measurements were carried out
approximately every month. First, the patient was treated by urinary
dilution and urinary crystal inhibition, then by PD, later HD was
added. Complications of dialysis (catheter septicemia, peritonitis)
arose as marked.
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oxalate increase followed by a brief splay between 6 and 9 h
from the end of HD, and resulting in a plateau phase. Because
of comparably lower concentrations of plasma oxalate during
an HD session and in the early phase of rebound, the removal
of oxalate via urine and PD is supposed to be lower than in the
later phases of rebound. However, in our case, only one
measurement (marked by *) was carried out that could
support this. Thus, a sensible timing of PD and HD session
has to be applied, for instance, continuous cyclic peritoneal
dialysis at night and HD in the morning.
The aim of lowering plasma oxalate concentration below
the level at the start of intensified dialysis was accomplished
in only four of six patients. Imperfect compliance and
complications of RRT account for the failure in the other two
patients. Although many means of optimizing RRT have been
undertaken, pre-dialysis plasma oxalate concentrations could
not be lowered below the level of supersaturation in five of
the six patients. Also, the data on total removal show that
there still is a considerable gap between estimates of oxalate
production and oxalate removal rates achieved. However,
taking into account the comparably low concentrations of
plasma oxalate of patients A and C, their oxalate removal
rates cannot be compared with the oxalate generation rates of
Marangella’s patients.6 Patients B, D, E, and F with mean pre-
dialysis plasma oxalate concentrations between 111 and
137 mmo/l had oxalate removal rates between 19.6 and
24.1 mmol/week/1.73 m2. These figures come close to the
range of Marangella’s estimates of oxalate generation (28.9
and 37.7 mmol/week) in two adult male patients with pre-
dialysis plasma oxalate concentrations of 123 and 161 mmo/l.
The dialysis intensity of our patients was very high. Their
total creatinine clearance (that includes residual renal
function) was two to three times higher than 60 l/week/
1.73 m2 that are required in the guidelines for HD adequacy
by the National Kidney Foundation.14
Intensified dialysis programs demand a high motivation
for treatment from patients and their families to balance the
acute loss of quality of life. Compliance will depend on the
distance between home and dialysis center, parent’s involve-
ment in job, social support by relatives and neighbors,
financial situation, and not at least on age and demands of
siblings. The medical and psychosocial staff can support the
family by promoting good understanding of disease and
treatment options, organizing accommodation nearby the
dialysis center (both for in- and outpatients) and giving
psychosocial assistance.
The ultimate therapy for pediatric patients with pyrodix-
ine-resistant PH1 is early transplantation of liver and kidney,
with dialysis serving as a temporary therapy. Production rate
of oxalate and the amount of oxalate already deposited in
various organs differ from patient to patient. Therefore,
patients need their individual prescription of dialysis. Some
rough guidelines are given:
K Dialysis should be started before ESRF has devel-
oped. At the same time, transplantation has to be
prepared for. The fact that the amount of total
accumulated body oxalate determines long-term
outcome of patients with PH13 seems to justify an
early start of dialysis (glomerular filtration rate
between 20 and 30 ml/min/1.73 m2), with the aim to
keep plasma oxalate below the threshold of 50 mmol/
l. By slowing down intra- and extrarenal accumula-
tion of calcium oxalate, residual renal function
might be preserved longer, which is of high value,
particularly as we could show that even in case of
ESRF renal elimination of oxalate accounts for a
major part.
K The form of RRT will depend on the level of plasma
oxalate, estimated total body oxalate, age of the
patient, previous history (e.g. thrombosis of central
veins), expected length of treatment (e.g. planned
living-donor LTX), as well as logistic and social
needs. In case of sequential liver and kidney
transplantation, dialysis might be necessary after
LTX. The existence of an HD access will be of help
then.
K PD treatment can be intensified by adjusting dwell
time and dwell volume according to peritoneal
equilibration test. The more cycles/exchanges per
day are chosen, the more oxalate is removed.
K For intensive HD, the most efficient high flux
hemodialyzer (X1 m2 capillary surface per 1 m2 body
surface area) and a maximal blood flow rate
(X150–200 cm3/min/m2 body surface area) should
be applied. Additional sessions per week rather than
additional time per session improve oxalate removal.
K For some patients, a combination of PD and HD
might be a further option of treatment. However,
a sensible timing of PD and HD session has to be
applied.
K To prevent organ damage resulting from a growing
total oxalate burden, it seems justified to prescribe as
much dialysis as the patient and the family can
tolerate. If possible, plasma oxalate should be kept
below the threshold for supersaturation of 50mmol/l.
MATERIALS AND METHODS
Six patients underwent treatment for PH1 in our hospital between
1997 and 2004. Patients A to D were referred to our hospital.
Patients E and F were diagnosed at our center.
Patient demographics and case histories are summarized in
Table 4. In no case was there a positive family history of PH1 or
consanguinity. The diagnosis of PH1 was confirmed by a reduced
activity of AGT enzyme in the liver. The median age at the time of
diagnosis was 3.3 years (range 0.4–7.5 years). None of the patients
was significantly responsive to a therapy by pyridoxine.
Management of the patients included preserving maximal
diuresis, adequate nutrition, good control of acidosis, administra-
tion of recombinant human erythropoietin and recombinant human
growth hormone, and standard infant dialysis therapy with conti-
nuous cyclic peritoneal dialysis or high flux polysulfone HD or both.
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Convective transport by ultrafiltration was not differentiated, as
hemodiafiltration was not applied and therefore ultrafiltration
clearance did not exceed 2% of total clearance.
Treatment regimen, blood flow rate (QB), type of hemodialyzer,
dwell volume, and number of exchanges are outlined in Table 2.
Peritoneal equilibration test was performed as instituted at our
center.15
Dialysate was acidified with 25% concentrated hypochloric acid
immediately after each exchange and pH tested to beo3. All samples
of whole dialysate were stored at 41C in a plastic tank over 24 h. After
mixing, samples of 10 ml were taken and stored at 201C for 24 h
maximum before measurement. After 10-fold dilution with 0.3 mol/l
boric acid, oxalate concentration was measured by a modified ion
chromatography method as described by von Schnakenburg et al.16
Urine collection over 24 h, preparation of samples, and analysis of
oxalate concentration was handled likewise. Blood samples of 2 ml
were placed in ice-cooled heparinized vials and immediately
centrifuged at 1000 g for 10 min at 41C. After storage at 701C for
24 h maximum before measurement, 1 ml of this plasma was
ultrafiltrated at 1500 g for 20 min at 41C using a centrisart I
ultrafiltration vial (Sartorius, Germany). The ultrafiltrate was diluted
10-fold and analyzed for oxalate concentration by the above-
mentioned modified ion chromatography method immediately.
Blood samples in PD were drawn at the start of collecting time of
urine and dialysate. Concentration of oxalate was determined in
whole urine, whole dialysate, respectively. Oxalate clearance by
urine was determined by the equation: ClearanceOxalate ¼
OxalateUrine VolumenUrine/OxalatePlasma, related to collecting
time (1440 min) and corrected to 1.73 m2 body surface area.
Oxalate clearance by PD was determined by the equation: Clear-
anceOxalate¼OxalateDialysateVolumenDialysate/OxalatePlasma, related to
sampling time (1440 min) and corrected to 1.73 m2 body surface area.
Removal of oxalate by urine was determined by OxalateUrine 
VolumenUrine related to time. Removal of oxalate by dialysate was
determined by OxalateDialysate VolumenDialysate related to time.
Blood samples in HD were drawn at start, 30 min thereafter,
30 min before, and 30 min after the end of each HD session. Oxalate
kinetics are based on the concentration versus time relationship:
ct ¼ cinitialeKt=V , where ct is the concentration of plasma oxalate at
time t, cinitial is the concentration of plasma oxalate at start of HD, V
is the volume of distribution, and dialysance K at time t was
calculated by
QB½ðct ; pre  dialyzer  ct; postdialyzerÞ=ðct; predialyzerÞ;13
where QB is the blood flow rate. Removal at time t was estimated
by
QBðct ; pre  dialyzer  ct; postdialyzerÞ:
For data on averaged daily removal by HD, removal of one HD
session was multiplied by the number of sessions per week and
divided by seven. Averaged daily dialysance was determined
likewise.
Total creatinine clearance was estimated by the Schwartz
formula.17
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protein) Presentation of PH1
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Age at
start of dialysis
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15 0.8
E M 7.5 3.3 Nephrocalcinosis 14 13
F F 0.4 1.4 Nephrocalcinosis on routine
ultrasound
15 0.7
AGT, alanine-glyoxylate-aminotransferase; PH1, primary hyperoxaluria type 1; CCr, creatinine clearance.
aLiver biopsy.
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